S12 Ep23: Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc

from OncLive® On Air · host OncLive® On Air

Dr Kaklamani discusses the mechanism of action of inavolisib, the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm, and considerations for early biomarker testing in patients with breast cancer.

Episode metadata supplied by the publisher feed · Published Mar 10, 2025

Embed this episode

Attribution link and audio player

Ready to play

S12 Ep23: Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc

0:00 5:27

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 5 minutes long.

When was this OncLive® On Air episode published?

This episode was published on March 10, 2025.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!